Cipla launches mobile application for asthma screening

07 Jan 2025 Evaluate

Cipla has launched a mobile application designed to enable the first line of screening for asthma in India. According to the Global Burden of Disease report, the total burden of asthma in India is estimated to be around 34.3 million. India has a three-fold higher mortality rate and two-fold higher asthma-associated disability burden compared to the global proportion.

Earlier, the company had obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza (insulin human) Inhalation Powder in India. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 15:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1520.55
Zydus Lifesciences 933.10
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×